The paper emphasizes the potential of Lipella’s investigational therapy, LP-310, a novel oral rinse formulation of LP-10 (tacrolimus) specifically designed to provide localized therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback